Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             52 results found
no title author magazine year volume issue page(s) type
1 Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed? Sarawate, Chaitanya A.
 2007
 29 Supplement C p. 196-209
14 p.
 article
2 A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin Rogers, Sophie L.
 2007
 29 Supplement C p. 242-252
11 p.
 article
3 A Model for Assessing the Cost-Effectiveness of Atorvastatin and Simvastatin in Achieving Canadian Low-Density Lipoprotein Cholesterol Targets Lachaine, Jean
 2007
 29 Supplement C p. 519-528
10 p.
 article
4 An Evaluation of patients' preferences for osteoporosis medications and their attributes: The PREFER-international study Duarte, Jesús Walliser
 2007
 29 Supplement C p. 488-503
16 p.
 article
5 A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain Beaulieu, André D.
 2007
 29 Supplement C p. 49-60
12 p.
 article
6 A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in african american and hispanic american patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy Davidson, Jaime A.
 2007
 29 Supplement C p. 1900-1914
15 p.
 article
7 A 12-Week, Prospective, Open-Label Analysis of the Effect of Rosuvastatin on Triglyceride-Rich Lipoprotein Metabolism in Patients with Primary Dyslipidemia Kostapanos, Michael S.
 2007
 29 Supplement C p. 1403-1414
12 p.
 article
8 Cardiac involvement in fabry disease:About numbers and notions Strotmann, J.
 2007
 29 Supplement C p. S22-S23
2 p.
 article
9 Cholesterol reduction yields clinical benefits: meta-analysis including recent trials Gould, A. Lawrence
 2007
 29 Supplement C p. 778-794
 article
10 Clinical benefits of early treatment with Fabrazyme in Fabry disease Waldek, S.
 2007
 29 Supplement C p. S29-
1 p.
 article
11 Clinical characteristics of Hungarianpatients with fabry disease Rákóczi, E.
 2007
 29 Supplement C p. S19-
1 p.
 article
12 Comparison of Botulinum Neurotoxin Preparations for the Treatment of Cervical Dystonia Chapman, Mary Ann
 2007
 29 Supplement C p. 1325-1337
13 p.
 article
13 Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): A randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults Antonijoan, Rosa
 2007
 29 Supplement C p. 814-822
 article
14 Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, open-label, dose-titration study in korean patients with hypercholesterolemia Hak Lee, Sang
 2007
 29 Supplement C p. 2365-2373
9 p.
 article
15 Data Gathering: Early and Often Daniel Mullins, C.
 2007
 29 Supplement C p. 1750-
1 p.
 article
16 Deterioration of renal function in young adult patients with fabry disease and proteinuria Bichet, D.G.
 2007
 29 Supplement C p. S33-
1 p.
 article
17 Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain: Evidence-Based Findings from Post Hoc Analysis of Three Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Studies Kajdasz, Daniel K.
 2007
 29 Supplement C p. 2536-2546
11 p.
 article
18 Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: An exploratory analysis of archived samples using two commercially available techniques Ose, Leiv
 2007
 29 Supplement C p. 2419-2432
14 p.
 article
19 Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: A prospective, nonrandomized, crossover study in patients coinfected with hepatitis c and hiv receiving methadone maintenance treatment Berk, Steven I.
 2007
 29 Supplement C p. 131-138
8 p.
 article
20 Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial LaForce, Craig
 2007
 29 Supplement C p. 1579-1590
12 p.
 article
21 Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study Davidson, Michael H.
 2007
 29 Supplement C p. 1354-1367
14 p.
 article
22 Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase ii, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease Besarab, Anatole
 2007
 29 Supplement C p. 626-639
14 p.
 article
23 Fabry disease and bilateral renal cell carcinoma Herrero, J.J.
 2007
 29 Supplement C p. S28-
1 p.
 article
24 Fabry disease: classic phenotype in alarge family affected by a novel mutation (A292T) in the α-galactosidase a gene Spanu, C.
 2007
 29 Supplement C p. S26-
1 p.
 article
25 Fabry disease: Worsening of hearingloss with enzyme replacement therapy Moura, C.
 2007
 29 Supplement C p. S34-
1 p.
 article
26 Factors related to antipsychotic oversupply among central Texas Veterans Yang, Min
 2007
 29 Supplement C p. 1214-1225
12 p.
 article
27 Formation of neutralizing antibodies in patients receiving botulinum toxin type a for treatment of poststroke spasticity: A pooled-data analysis of three clinical trials Yablon, Stuart A.
 2007
 29 Supplement C p. 683-690
8 p.
 article
28 Impact of treatment with agalsidasebeta on health-related quality of life in patients with Fabry disease Badia, X.
 2007
 29 Supplement C p. S31-
1 p.
 article
29 Influence of Antiretroviral Therapy on Oxidative Stress and Cardiovascular Risk: A Prospective Cross-Sectional Study in HIV-Infected Patients Masiá, Mar
 2007
 29 Supplement C p. 1448-1455
8 p.
 article
30 Intermitent long-term treatment in a patient with Fabry disease Del Pozo, C.
 2007
 29 Supplement C p. S32-
1 p.
 article
31 Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison Robbins, David C.
 2007
 29 Supplement C p. 2349-2364
16 p.
 article
32 Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial Derosa, Giuseppe
 2007
 29 Supplement C p. 602-610
9 p.
 article
33 Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials Buse, John B.
 2007
 29 Supplement C p. 139-153
15 p.
 article
34 Mixed Dyslipidemia Among Patients Using Lipid-Lowering Therapy in French General Practice: An Observational Study Van Ganse, Eric
 2007
 29 Supplement C p. 1671-1681
11 p.
 article
35 Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes Across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus Mullins, Peter
 2007
 29 Supplement C p. 1607-1619
13 p.
 article
36 Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years Kisicki, James C.
 2007
 29 Supplement C p. 1967-1979
13 p.
 article
37 Physical capacity and perception ofexertion in 72 patients with fabry disease Breunig, F.B.
 2007
 29 Supplement C p. S24-
1 p.
 article
38 Policy implications of drug importation Palumbo, Francis B.
 2007
 29 Supplement C p. 2758-2767
10 p.
 article
39 Prescript-assist™ probiotic-prebiotic treatment for irritable bowel syndrome: An open-label, partially controlled, 1-year extension of a previously published controlled clinical trial Bittner, Alvah C.
 2007
 29 Supplement C p. 1153-1160
8 p.
 article
40 Prevalence and treatment of dyslipidemia in canadian primary care: A retrospective cohort analysis Petrella, Robert J.
 2007
 29 Supplement C p. 742-750
9 p.
 article
41 Prevalence of fabry disease in malepatients with chronic renal disease not receiving renal replacement therapy: Preliminary report of a multicenter study Herrero, J.A.
 2007
 29 Supplement C p. S21-
1 p.
 article
42 Progressive development of microalbuminuria and proteinuria in males and females with fabry disease Ortiz, A.
 2007
 29 Supplement C p. S19-S20
2 p.
 article
43 Psychometric Testing and Validation of the Chronic Pain Sleep Inventory Kosinski, Mark
 2007
 29 Supplement C p. 2562-2577
16 p.
 article
44 Relationship between cardiac and kidneyinvolvement in fabry patients presenting with a classic phenotype Strotmann, J.
 2007
 29 Supplement C p. S22-
1 p.
 article
45 Relationship between chronic renal disease, blood pressure, and left ventricular hypertrophy in males and females with Fabry disease Ortiz, A.
 2007
 29 Supplement C p. S21-S22
2 p.
 article
46 The author's reply Mullins, C. Daniel
 2007
 29 Supplement C p. 383-384
2 p.
 article
47 The importance of motivating junior scholars Mullins, C. Daniel
 2007
 29 Supplement C p. 722-
1 p.
 article
48 The long-term effect of enzyme replacement therapy on regression of left ventricular hypertrophy in patients with Fabry cardiomyopathy. Impact of baseline findings Strotmann, J.
 2007
 29 Supplement C p. S30-
1 p.
 article
49 The role of geography in health care dissemination Mullins, C. Daniel
 2007
 29 Supplement C p. 358-
1 p.
 article
50 Titration patterns with rosuvastatin as compared with other statins in clinical practice: A retrospective observational cohort study using an electronic medical record database Fox, Kathleen M.
 2007
 29 Supplement C p. 2385-2394
10 p.
 article
51 Use of patient-reported sleep measures in clinical trials of pain treatment: a literature review and synthesis of current sleep measures and a conceptual model of sleep disturbance in pain Cole, Jason C.
 2007
 29 Supplement C p. 2580-2588
9 p.
 article
52 Using indirect comparisons in pharmacoeconomic studies—Time for implementation Malone, Daniel C.
 2007
 29 Supplement C p. 2454-2455
2 p.
 article
                             52 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands